Supplementary Tables 1 - 5 and Figures 1 - 3 from Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
posted on 2023-04-03, 14:29authored byWim Dokter, Ruud Ubink, Miranda van der Lee, Monique van der Vleuten, Tanja van Achterberg, Danielle Jacobs, Eline Loosveld, Diels van den Dobbelsteen, David Egging, Ellen Mattaar, Patrick Groothuis, Patrick Beusker, Ruud Coumans, Ronald Elgersma, Wiro Menge, John Joosten, Henri Spijker, Tijl Huijbregts, Vincent de Groot, Michel Eppink, Guy de Roo, Gijs Verheijden, Marco Timmers
Supplementary tables describe a comparison of half-lives of SYD983 in the different species (Table S1), PK details in mice (Table S2), PK details in tumor-bearing mice (Table S3), PK details in cynomolgus monkeys (Tables S4 and S5), Flow rates of SYD983 in RP-HPLC, HIC profile of SYD983 and SYD985 (Figure S1), Cytotoxicity of SYD983 versus SYD985 (Figure S2), and control staining for IHC of the tumors used in PDX (Figure S3).